The manufacturer, based on recent laboratory data, has announced that a third dose of the combined vaccine from Pfizer and BioNTech is effective against the omicron variant of the coronavirus. In a press release. The third dose produces twenty-five times more neutralizing antibody titers in the body than the first two doses, a result similar to that given in the first two doses against the original virus.
Since most of the important spiny protein epitopes targeting T cells were unaffected by omicron mutations, two doses of Pfizer likely protected against severe disease. However, the company continues to research a vaccine adapted to Omicron
The results are largely consistent with a preliminary study published by researchers at the South African Institute of Health Research on Tuesday that Omicron is able to partially circumvent the protection offered by two doses of the Pfizer/BioNTech vaccine.
It’s important to note that the experiments were done in a lab and more research is needed to confirm anything. So far, even science knows very little about omicrons.
